Clinical trial
A Phase 2a, Multi Centre, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Effect of 12 Weeks Treatment With Oral PXS-4728A on Microglia Activation, as Measured by Positron Emission Tomography, in Participants With Isolated Rapid Eye Movement Sleep Behavior Disorder
NCT05904717 is registered in ClinicalTrials.gov with Syntara as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2a, Multi Centre, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Effect of 12 Weeks Treatment With Oral PXS-4728A on Microglia Activation, as Measured by Positron Emission Tomography, in Participants With Isolated Rapid Eye Movement Sleep Behavior Disorder
- Lead sponsor
- Syntara
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- November 8, 2023
- Completion date
- September 30, 2026
- Enrollment
- 40 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.